SETD7 and breast cancer: TRIM21/Ro52 also negatively regulates the SET domain containing 7, histone lysine methyltransferase (SETD7, also known as SET7/9), which is involved in breast cancer cell proliferation, migration, and invasion, such that higher expression of TRIM21/Ro52 is associated with better outcomes in these patients [45].